Document is current
Any future updates will be listed below
-
Authors
Nunes, Jessica
Tafesse, Rakeb
Mao, Charlene
Purcell, Matthew https://orcid.org/0000-0001-7425-8213
Mo, Xiaokui https://orcid.org/0000-0002-9797-2687
Zhang, Liwen https://orcid.org/0000-0003-1696-9652
Long, Meixiao
Cyr, Matthew G.
Rader, Christoph
Muthusamy, Natarajan https://orcid.org/0000-0002-0351-4504
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21 CA229961-01)
- License Information
-
More Information
Article History
Received: 30 January 2023
Accepted: 8 May 2024
First Online: 18 June 2024
Competing interests
: The authors C.R. and M.G.C. are inventors of two patent applications for recombinant human antibodies targeting Siglec-6 and their applications, listed below: (i) U.S. Patent 8,877,199 for B Cell Surface Reactive Antibodies. Assignee: U.S. Department of Health and Human Services (Washington, DC, USA). (ii) PCT/US2022/079656 for Siglec-6 Antibodies, Derivative Compounds and Related Uses. Assignee: University of Florida Research Foundation, Inc. (Gainesville, FL, USA). The other authors do not declare any competing interests.
